New Rochelle, NY, December 11, 2014--In cases of traumatic brain injury (TBI), predicting the likelihood of a cranial lesion and determining the need for head computed tomography (CT) can be aided by measuring markers of bone injury in the blood. The results of a new study comparing the usefulness of two biomarkers released into the blood following a TBI are presented in Journal of Neurotrauma, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Journal of Neurotrauma website at http://online.
The article "GFAP Out-Performs S100ß in Detecting Traumatic Intracranial Lesions on Computed Tomography in Trauma Patients with Mild Traumatic Brain Injury and Those with Extracranial Lesions," describes a study of adult trauma patients with and without mild or moderate TBI. The authors, Linda Papa and colleagues from Orlando Regional Medical Center, North Florida Veteran's Health System and University of Florida (Gainesville), University of Central Florida (Orlando), Banyan Biomarkers Inc. (Alachua, FL), Virginia Commonwealth University (Richmond, VA), and Baylor College of Medicine (Houston, TX), showed that increased blood levels of glial fibrillary acidic protein (GFAP) following TBI was a good predictor of intracranial lesions, whether or not the patient had fractures elsewhere in the body. Whereas S100ß levels in the blood of were significantly higher in trauma patients with fractures than without fractures, it was not as useful as GFAP in distinguishing between intracranial and extracranial lesions.
John T. Povlishock, PhD, Editor-in-Chief of Journal of Neurotrauma and Professor, Medical College of Virginia Campus of Virginia Commonwealth University, Richmond, notes that "This is an extremely important paper because of its relatively large sample size and its singular focus upon mild traumatic brain injury complicated by the presence of extracranial lesions. This study convincingly demonstrates the efficacy and brain specific nature of GFAP and its ability to detect traumatic intracranial lesions while also calling into question the overall utility of S100ß in the same patient population. Importantly, the superior performance of GFAP in the mild brain injured population is an important observation consistent with other reports emerging in the field. Lastly, the observation that these GFAP elevations occur relatively early in a posttraumatic course speaks to the potential utility of using these biomarkers to screen brain injured patients who then may require more extensive and/or long term imaging studies."
About the Journal
Journal of Neurotrauma is an authoritative peer-reviewed journal published 24 times per year in print and online that focuses on the latest advances in the clinical and laboratory investigation of traumatic brain and spinal cord injury. Emphasis is on the basic pathobiology of injury to the nervous system, and the papers and reviews evaluate preclinical and clinical trials targeted at improving the early management and long-term care and recovery of patients with traumatic brain injury. Journal of Neurotrauma is the official journal of the National Neurotrauma Society and the International Neurotrauma Society. Complete tables of content and a sample issue may be viewed on the Journal of Neurotrauma website at http://www.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in promising areas of science and biomedical research, including Therapeutic Hypothermia and Temperature Management, Brain Connectivity, and Tissue Engineering. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website at http://www.